Quality of life utility values for hereditary haemochromatosis in Australia

from Most Recent Articles: Health and Quality of Life Outcomes at http://bit.ly/1RBsv17 on February 29, 2016 Hereditary hemochromatosis (HH) is a common autosomal recessive disorder amongst persons of northern European heritage. If untreated, iron accumulates in parenchymal tissues causing morbidity and mortality. As…

Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation

from Latest Results for Applied Health Economics and Health Policy at http://bit.ly/1Lrg4Wi on February 29, 2016 Abstract Background Atrial fibrillation (AF) poses a significant economic burden. An increasing number of interventions for AF require cost-effectiveness analysis with decision–analytic modeling to demonstrate value. However, high-quality cost estimates of AF that can be used to inform decision–analytic […]

Effectiveness and Cost of a Personalized Reminder Intervention to Improve Adherence to Glaucoma Care

from Latest Results for Applied Health Economics and Health Policy at http://bit.ly/21EoIES on February 29, 2016 Abstract Background Glaucoma is the leadi ng cause of irreversible blindness in the USA. Glaucomatous vision loss is preventable with proper eye care, including appointment adherence. Therefore, interventions that improve appointment adherence can reduce the number of patients with […]


from ISPOR News & Press Releases at http://bit.ly/1nbw1Vc on February 29, 2016 at 01:34PM Princeton, NJ—February 29, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced its candidates today for open positions on the 2016–2017 Board of Directors. The Board of Directors drives ISPOR’s strategic direction and is responsible for the management of… Read […]

The virtues and vices of the WHO

from The Incidental Economist at http://bit.ly/1pkw3vG on February 29, 2016 at 01:00PM The World Health Organization’s dismal handling of the Ebola outbreak has led to calls for sweeping reforms to the world’s system for managing infectious disease. The consensus view, though, is that we shouldn’t start from scratch. Laurie Garrett captures the prevailing wisdom in […]

P4P in Medicaid

from Healthcare Economist at http://bit.ly/1Re5izv on February 29, 2016 at 03:20AM Does Medicaid use pay-for-performance (P4P) for providers?  If so, how does it work?  And does it affect quality and cost? These are the questions of interest to Rosenthal et al. (2015) in their study of P4P programs in Alabama, Minnesota, and Pennsylvania.  Although all […]

Congress’ Drug Addiction

from Care And Cost at http://bit.ly/1UqiC9g on February 27, 2016 at 12:11PM   Posted 2/26/16 on Employee Benefit News. The Congressional committee that recently demanded Martin Shkreli’s appearance must have hoped to spotlight a smug jerk responsible for the outrageous prescription drug pricing that we’re all up against. Of course there are lots of Shkrelis running […]